

The Funding Landscape for Small Biopharma Ventures, 2010-2015: Trends, strategies and priorities

Table of Contents

The funding landscape for small biopharma ventures, 2010-2015	
Executive Summary	10
Macroeconomic trends and implications	10
Accelerating biopharma collaboration	11
Valuing investment opportunities in small biopharma	12
Priorities and preferences of private investors	13
Top-line trends in venture financing	14
Investment choices of most active firms in 2009	14
Chapter 1 Macroeconomic trends and implications	18
Summary	18
Introduction	19
Recent events	19
Supply side factors- higher cost of capital	20
Demand side factors- Decreased earnings potential	21
Provider-level constraints	23
Patient-level implications	25
Short and long term implications	26
Non-dilutive funding in an era of excessive dilution	29
Research grants and government contracts	30
Incentives of non-profit foundations	31
Government incentives and associated initiatives	33
Issues surrounding NDF from non-profit agencies	34
Chapter 2 Accelerating biopharma collaboration	38
Summary	38
Accelerating biopharma collaboration	39
Rapidly evolving deal structures	43
De-risking R&D via options-based investing	44
Due diligence in biopharma alliances	47
Marketing agreement	49
Licensing arrangement/Product acquisition	50
Joint venture	50
Alliance/Corporate partnering	51
Outright acquisition of a company	52
Conclusions	52
Chapter 3 Valuing investment opportunities in small biopharma	54
Summary	54
Introduction	55
Valuation methods and usage	55
Discounted cash flow	56
Risk-adjusted net present value	57
Real options	57
Comparables	58
Assessing commercial potential	60
Sales potential	61
Pricing and positioning	62
Cost of commercialization	65
Chapter 4 Priorities and preferences of private investors	68
Summary	68
Introduction	69
Stages of investment	69
Investors: definition, overview	72
Distinction between private equity and venture capital funds	72
Angel investors	73
Venture capital funds	74

- Mezzanine investors 74
- Venture investors versus buyout investors 75
- Process of getting new investment 77
- Term sheets 78
- Type of security 79
- Board representation 80
- Valuation 82
- Capital expenditure 83
- Single versus multiple investors 84
- Investor priorities in the new landscape 85
- Market attractiveness and product-market-focus 86
- The organization 87
- Financials 87
- Business plan 88
- Assessment of risks 88
- Intellectual property protection 89
- Chapter 5 Top-line trends in venture financing 92
- Summary 92
- How to use this chapter 93
- Definition of key terms 94
- Venture financing 94
- Seed 94
- Start-up 94
- Early stage 95
- Growth/expansion capital 95
- Later stage 95
- Mezzanine 96
- Bridge loan 96
- Private placement 96
- Other 96
- Countries attracting the most venture financing 97
- Recent trends 98
- Conclusions 99
- Distribution of venture financing rounds by investment stage 100
- Recent trends 101
- Further analysis of financing rounds by stage 103
- Conclusions 105
- Chapter 6 Investment choices of most active firms in 2009 108
- Summary 108
- Most active venture capital investors in 2009 109
- Analysis of investment preferences 110
- Therapeutic areas of focus 110
- Investment destinations by geography 113
- Stage of investments 114
- Two types of venture investors 115
- Corporate Venture Capital (CVC) funds 116
- Emerging role of CVC in Life Sciences 116
- Strategic motivations 117
- Novartis Venture Fund 119
- Novo A/S, Denmark 121
- Independent venture capital funds 125
- SV Life Sciences 125
- Investment focus in 2009 125
- Texas Coalition for Capital 127
- Chapter 7 Appendix 129
- Research methodology 129
- Index 132

List of Figures

Figure 1.1: Components of government healthcare expenditure in US, 2008 22

Figure 1.2: Market share of generic medicines in Europe, 2007 (by volume)	24
Figure 1.3: IPOs have recently reappeared at a low level	28
Figure 1.4: Grant-making focus of Bill & Melinda Gates Foundation	32
Figure 2.5: How biotech entrepreneurs hope to deal with the financial crisis	39
Figure 2.6: Reliance of big pharma on R&D externalization	41
Figure 2.7: Trends in biotech-pharma deals by development stage	42
Figure 2.8: Overview of partnering issues	44
Figure 2.9: Option agreements by top 20 pharma companies (≤Phase I)	46
Figure 2.10: Reliance on the option model varies by company	47
Figure 2.11: Deal structures and responsibilities	48
Figure 3.12: Primary valuation methodology by investor type, 2009	59
Figure 3.13: Assessing the net earnings potential of a medical intervention	60
Figure 3.14: Assessing revenue potential	61
Figure 3.15: Pricing and positioning	63
Figure 3.16: Impact of incoming therapies on payor budgets	64
Figure 3.17: Development and commercialization costs	65
Figure 4.18: Company growth stages and funding sources	71
Figure 4.19: The deal “funnel” at a typical VC firm	77
Figure 4.20: Sequence of documents	78
Figure 4.21: Board size: advantages and limitations	81
Figure 5.22: Geographic distribution of venture financing rounds	97
Figure 5.23: Trends in geographic distribution of venture financing rounds	98
Figure 5.24: US investments by region, 2008-2009	99
Figure 5.25: Total number of financing rounds by stage, 2004-2010	100
Figure 5.26: Distribution of financing rounds by stage, 2004-2010	101
Figure 5.27: Trends in financing rounds by stage, 2004-2019	102
Figure 5.28: Early-stage funding by type, 2004-2010	103
Figure 5.29: Mid-stage funding by type, 2004-2010	104
Figure 5.30: Late-stage funding by type, 2004-2010	105
Figure 6.31: Preferences of top 15 venture finance investors, 2009	111
Figure 6.32: Preferences of top 15 venture finance investors, 2009	113
Figure 6.33: Number of deals by investment stage, 2009	114
Figure 6.34: R&D performance scorecard	118
Figure 6.35: Novartis Venture Fund investments in 2009	120
Figure 6.36: Novo A/S ownership structure	122
Figure 6.37: Novo A/S investments, 2000-2008	123
Figure 6.38: Novo A/S investments in 2009	124
Figure 6.39: SV Life Sciences investments in 2009	126
Figure 6.40: Texas Coalition for Capital investments in 2009	128

List of Tables

Table 1.1: Non-dilutive sources of funding	30
Table 2.2: Established and evolving deal structures	43
Table 2.3: Incentives in a strategic licensing arrangement	50
Table 3.4: Overview of valuation methods	56
Table 4.5: Stages of equity investing	70
Table 6.6: Most active venture investors in 2009	109
Table 6.7: R&D focus of top 15 venture investors, 2009	110